Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Galunisertib

Galunisertib

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Galunisertib

5 trials tracked of Galunisertib: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 86 citations.

5Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 3 Phase 1 1
  1. Phase 3 A Study of Galunisertib in Participants With Myelodysplastic Syndromes Completed · 86 cited
  2. Phase 2 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Completed
  3. Phase 2 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer Completed
  4. Phase 2 A Study in Recurrent Glioblastoma (GB) Completed
  5. Phase 1 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.